(Q38074121)

28 August 2017

1 reference

title

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors (English)

1 reference

metastatic renal cell carcinoma

28 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Robert A Figlin

1

1 reference

28 August 2017

Isabelle Kaufmann

series ordinal

2

1 reference

28 August 2017

Jillian Brechbiel

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

12 February 2013

1 reference

International Journal of Cancer

28 August 2017

1 reference

28 August 2017

133

1 reference

28 August 2017

4

1 reference

28 August 2017

788-796

1 reference

28 August 2017

Global cancer statistics

1 reference

21 January 2018

Cancer statistics, 2012

1 reference

Metastatic renal cell carcinoma

21 January 2018

1 reference

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

21 January 2018

1 reference

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

21 January 2018

1 reference

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices

21 January 2018

1 reference

Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein

21 January 2018

1 reference

Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

mTOR signaling pathway and mTOR inhibitors in cancer therapy

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

21 January 2018

1 reference

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1

21 January 2018

1 reference

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling

21 January 2018

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation

21 January 2018

1 reference

Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.

21 January 2018

1 reference

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

21 January 2018

1 reference

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

21 January 2018

1 reference

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

21 January 2018

1 reference

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer

21 January 2018

1 reference

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

21 January 2018

1 reference

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28023

1 reference

28 August 2017

1 reference